2x-121
Recurrent Small Cell Lung Cancer
VA Office of Research and DevelopmentPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Imatinib National Cancer Institute (NCI) | Phase 2 | B |
Bendamustine Charite University, Berlin, Germany | Phase 2 | CCC |
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
Devimistat Wake Forest University Health Sciences | Phase 1 | CC |
Same molecule, other indications
2x-121 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →